Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. Further Reading.
https://www.google.com/url?rct=j&sa=t&url=https://www.defenseworld.net/2022/07/17/vittal-vasista-sells-4332-shares-of-regenxbio-inc-nasdaqrgnx-stock.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw2d3xarfpBOCUciJ5b6g5WT
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.